Who
Lisa A. Conte
Director and Officer
Company insider
Files Form 4 as: CEO and President, Jaguar Health.
In numbers
- Trades disclosed
- 42
- Buys
- 2
- Sells
- 0
- Bought
- $22K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Jun 2016
- Last trade
- 11 Dec 2025
- Last filed
- 21 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —28,592 at $0.00 | filing |
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,592 at $0.00 | filing |
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,592 at $0.00 | filing |
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —28,592 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code D | $450.0M9,000 at $50,000.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | $473.1M9,462 at $50,000.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,262 | filing |
| 17 May 2025filed 20 May 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code M | —2 at $0.00 | filing |
| 17 May 2025filed 20 May 2025 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —2 | filing |
| 31 Mar 2025filed 2 Apr 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code P | $450.0M9,000 at $50,000.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code P | —9,000 | filing |
| 8 Oct 2024filed 10 Oct 2024 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —132,020 at $0.00 | filing |
| 8 Oct 2024filed 10 Oct 2024 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —16,503 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,695 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —2,695 | filing |
| 5 Apr 2024filed 17 Apr 2024 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —600 at $0.00 | filing |
| 5 Apr 2024filed 17 Apr 2024 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —600 | filing |
| 14 Aug 2023filed 14 Aug 2023 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —383,605 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,694 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —2,694 | filing |
News
Jaguar Health, Inc.: Jaguar Health Provides Update Regarding Special Stock DividendJAGX · finanznachrichten.de · 14 Oct 2026Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock DividendJAGX · tennesseedaily.com · 13 Oct 2026Jaguar Animal Health (NASDAQ:JAGX) Upgraded at Wall Street ZenJAGX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Lisa A. Conte; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.